Carcinogenicity of the N-hydroxy derivative of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline and 3,2'-dimethyl-4-aminobiphenyl in the rat

Citation
Cl. Archer et al., Carcinogenicity of the N-hydroxy derivative of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline and 3,2'-dimethyl-4-aminobiphenyl in the rat, CANCER LETT, 155(1), 2000, pp. 55-60
Citations number
22
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
CANCER LETTERS
ISSN journal
0304-3835 → ACNP
Volume
155
Issue
1
Year of publication
2000
Pages
55 - 60
Database
ISI
SICI code
0304-3835(20000703)155:1<55:COTNDO>2.0.ZU;2-Y
Abstract
Heterocyclic amines and carcinogenic aromatic amines are similarly metaboli cally activated suggesting that they may have similar organ specificity. Th ree day-old male ACI/seg rats were injected, i.p., twice a week for 10 week s with 50 mu mol/kg of N-hydroxy-3,2'-dimethyl-4-aminobiphenyl (N-OH-DMABP; Group II), N-OH-2-amino-3,8-dimethylimidazo[3,5-f]guinoxaline (N-OH-MeIQx; Group III) ol N-OH-2-amino-1-methyl-6-phenylimidaza-[4,5-b]pyridine (N-OH- PhIP; Group IV). Animals in control group (Croup I) were similarly injected with solvent alone. The animals were sacrificed at age 68 weeks, and 31, 3 0, 27 and 31 rats from Groups I, II, III and IV, respectively. were evaluat ed. Colon carcinomas were found in 0, 15 (P < 0.001), 2 and 4 (P < 0.06), a nd bladder transitional cell tumors in zero, two, two and four (P < 0.06), in Group I, II, III and IV, respectively. The incidence of atypical hyperpl asia of ventral prostate in Groups ITT and IV, and of anterior prostate and seminal vesicle in all treated groups was also significantly greater (P < 0.05). These results suggest that N-OH-PhIP and N-OH-MeIQx may be potential carcinogens for the prostate. Since bladder tumor is rare in ACI rats, N-O H-PhIP may also be a potential carcinogen for the bladder. (C) 2000 Publish ed by Elsevier Science Ireland Ltd. All rights reserved.